0 0 8.78734622144562E-05 8.78734622144562E-05 8.78734622144562E-05 -0.00702987697715288 -0.000878734622144063 0.000790861159929731
Sign Up Today X
Thanks for submitting the form.
Stockreport

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). Gilead presented data on two novel, once-yearly formulations of lenacapavir for PrEP during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Data was also published in The Lancet. The data presented support the further development of once-yearly lenacapavir for PrEP. Gilead's shares have surged 56.8% in the past year against the industry's decline of 8.6%. Zacks Investment Research Image Source: Zacks Investment Research More on Gilead's Lenacapavir The phase I study evaluated the pharmacokinetics, safety and tolerability of two intramuscular single-dose 5000mg lenacapavir formulations. The study included 40 healthy adults at low risk of HIV acquisition, between 18 and 55 years of age, with a body mass index of less than or equal to 35.0 kg/m2. The data from the phas [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). Gilead presented data on two novel, once-yearly formulations of lenacapavir for PrEP during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Data was also published in The Lancet. The data presented support the further development of once-yearly lenacapavir for PrEP. Gilead's shares have surged 56.8% in the past year against the industry's decline of 8.6%. Zacks Investment Research Image Source: Zacks Investment Research More on Gilead's Lenacapavir The phase I study evaluated the pharmacokinetics, safety and tolerability of two intramuscular single-dose 5000mg lenacapavir formulations. The study included 40 healthy adults at low risk of HIV acquisition, between 18 and 55 years of age, with a body mass index of less than or equal to 35.0 kg/m2. The data from the phas [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS